Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3891657 | 0.91 | AURKA (0.53) | AURKANPC1RAB9A | |
| SCHEMBL3882164 | 0.89 | AURKA (0.47) | AURKASMN1; SMN2NPC1RAB9AFGFR1 | |
| SCHEMBL3882916 | 0.84 | KMT2A (0.44) | AURKAMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3879467 | 0.80 | AURKA (0.71) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL3879927 | 0.79 | AURKA (0.44) | AURKANTRK1KIT | |
| SCHEMBL3881861 | 0.78 | WNT1 (0.42) | AURKAMAPTLMNAKITFGFR1 | |
| SCHEMBL3883840 | 0.78 | TAAR1 (0.47) | — | |
| SCHEMBL1433941 | 0.77 | AURKA (0.69) | AURKAMAPK1CDC7CHEK1JAK2 | |
| SCHEMBL1895752 | 0.74 | AURKA (0.66) | AURKAMAPK1CDC7CHEK1JAK2 | |
| SCHEMBL1433403 | 0.74 | AURKA (0.66) | AURKAMAPK1CDC7CHEK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | disclosed |
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2006-07-20 | — | — | US | disclosed |
| EP-1534716-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007504-A1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | MAP2K2, MAP3K15, MAP3K5 | AURKA 239/4885LRRK2 536/4885MAPT 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.